Degree of fulfillment of the objectives of control metabolico and the factors of diabetic cardiovascular risk in patients type 2 in an area of primary attention;Grado de cumplimiento de los objetivos de control metabólico y de los factores de riesgo cardiovascular en pacientes diabéticos tipo 2 en un área de Atención Primaria

Anales de Medicina Interna

Volumn 22, Issue 11, 2005, Pages 520-524

  Gonzalez Sarmiento E ^a   Vielba Duenas B ^b   Fernandez Galante I ^a   Manso Garcia S ^b   San Pedro Martin Y ^b   Vielba Duenas D ^a   Fernandez Gonzalez R ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b Centro de Salud de Rondilla 2   (Spain)

Author keywords

Cardiovascular risk factors; DM type 2

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; GENERAL PRACTICE; MIDDLE AGED; RISK FACTOR; SPAIN;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SPAIN;

EID: 33644861957     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Banegas JR, Graciani A, Vilar F, Rodríguez-Artalejo F. Impacto de la diabetes en la mortalidad por enfermedades cardiovasculares en España. Med Clin Monogr (Barc) 2002; 3: 2-6
2. The World Health Report: life in the 21st century, a vision for all. Ginebra: OMS 1988
3. Sociedad Española de Arterioesclerosis y de la Sociedad Española de Diabetes. Dislipemia diabética: Documento de Consenso de la Sociedad Española de Arterioesclerosis y de la Sociedad Española de Diabetes. Clin Invest Arterioesclerosis 1998; 10: 55-64
4. Labarthe DR. Epidemiology and prevention of cardiovascular disease. A global challenge. Gaitthersburg, Md, Aspen Publisher, 1998
5. UKPDS Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional tratment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 1988; 352: 839-855.
6. O'Keefe J, Miles JM, Harris WH, Moe RM, McCallister BD. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc 1999; 74: 171-180.
7. American Diabetes Association. Standars of medical care for patiens with diabetes mellitus. Diabetes Care 2002; 25 (Supl. 1): 533-549
8. European Diabeters Polcy Group. A strategy for arterial risk assessment and management in type 2 diabetes mellitus. European Arterial Risk Policy Group on behalf of the International Diabetes Federation European Region. Diabet Med 1997; 14: 611-621
9. Expert Panel on Detection Evaluation and Treatment of Haigh Blood Cholesteterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation anf Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III) JAMA 2001; 285: 2486-2497.
10. Seventh Report of the Joint National Committee on Prevention,Detection, Evaluation, and Treatment of High blood presure (VII JNC). Chobanian et al. Hypertension 2003; 42: 1206-1252.
11. National Institutes of Health. Clinical guideliness on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998; 6 (Supl. 2): 51-209.
12. Pablo Velasco PL, Picó Alfonso A. Guías de Actuación Clínica de la Diabetes Mellitus. Endocrinol Nutr 2003; 50 (Supl.): 1-71
13. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 21 (Supl.1): S23-S31, 1998.
14. American Diabetes Association: Selfmonitoring of blood glucose (Consensus Statement). Diabetes Care 19 (Supl. 1): S62-S66, 1996.
15. Boland EA, Monsod T, Delucia M, Brand CA, Fernando S, Tamborlane WV: Limitations of conventional methods of self monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001; 24: 1858-1862.
16. Cañizo Gómez FJ, Moreira-Andrés MN. Control de los factores de riesgo cardiovascular y diabetes mellitus tipo 2. ¿Seguimos las recomendaciones?. Educación Diabetológica Profesional 2003; XIII(2): 13-23
17. CARE Trial. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardia infarction surviviors with average cholesterol levels. Circulation 1998; 98: 2513-9
18. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 334: 1383-1389
19. Mogensen CI. Microalbuminuria as predictor of clinical diabetes nephropathy. Kidney Int 1987; 31: 673-80
20. Björn Dalhöf, Richard Devereux, Sverre E Kjseldm, Stevo Julius, Gareth Beevers,Ulf de Faire et al: Losartan Intervention For Endpoint reduction in hypertension. Comentarios al estudio: Intervención para reducción de eventos finales en hipertensión con Losartan. Estudio LIFE. Comentarios Martín Rioboo E, García Criado E, Fonseca del Pozo FJ. Medicina de Familia (And) 2002; 4: 56: 58
21. Parving HH, Lehnert H, Brochner-Motensen J, Gomis R, Andersen S, Arner P. Then effect of Ibersartanof the developmenton diabetic of nepfropathy in patiens with type 2 diabetes. N Engl J Med 2001; 345: 870-8
22. Mogensen CE,Neldam S, Tikkanen I, Oren S, ViskoperR, Watts RW et al: Randomised controlled trialof dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria. (CALM) study. BMJ 2000; 321: 1440-4
23. Brenner Bm, Cooper Me, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nepropathy. N Engl J Med 2001; 345: 253-9.
24. Lewis Ej, Hunsicker LG, Clsrke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist ibersartan in patients with nepropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60
25. Aranda Lara P, Aranda Lara FJ, Aranda Granados PJ, López de Novales López E. Papel del bloqueo farmacológico del sistema renina-angiotensina en la protección del paciente con diabetes tipo 2. Hipertensión 2004; 20 (Supl. 2): 27-34
26. Gómez-Fernández P. Intervención sobre el sistema renina-angiotensina para la protección vascular del paciente hipertenso y en la nefropatía diabética. Rev Clin Esp 2004; 204: 596-600
27. Will J, Galuska D, Ford E, Mokdad A, Calle: Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective study. Int J Epidemiol 2001; 30: 540-546
28. George PB, Tobin KJ, Corpues RA, Devlin WH, O Newill WW. Treatment of cardiac risk factors in diabetic patients: how well do we follow the Guidelines? Am Heart J 2001; 142: 857-863.